Abstract
Association between the rates of poor outcomes in the patient cohort with acute coronary syndrome and polymorphisms G(−174)C in the IL6 gene and G(−1082)A in the IL10 gene were determined. In total, 1145 patients hospitalized for coronary artery disease to cardiological hospitals of Moscow, St. Petersburg, Kazan, Chelyabinsk, Perm, Stavropol, and Rostov-on-Don were examined. The mean observation period was 9.10 ± 5.03 months (maximal, 18 months). Analysis of the survival of the patients with acute coronary syndrome that carried allele A has demonstrated that the presence of IL10 gene polymorphism G(−1082)A is associated with more frequent poor outcomes as compared with GG genotype. The survival time to endpoint for the carriers of GA and AA genotypes was 11.68 ± 0.67 months versus 12.69 ± 0.65 months for the carriers of GG genotype in IL10 gene (χ2 = 4.13, p = 0.042). As for the IL6 gene polymorphism G(−174)C, survival rate analysis did not detect any significant association with the risk for poor outcome. However, joint analysis of these polymorphisms in both genes has demonstrated that characteristic of the patients with acute coronary syndrome that carry GG genotype of IL6 gene and GA and AA genotypes of IL10 is a higher rate of poor outcomes (time to endpoint, 11.01 ± 1.24 months) as compared with the carriers of IL6 gene CC and CG genotypes and IL10 gene GG genotype (time to endpoint, 13.28 ± 0.83 months (ξ2 = 10.23, p = 0.017). These data suggest that the genes IL6 and IL10, whose products are involved in the control of inflammatory response, play an important role by increasing the probability of poor outcomes in the patients with acute coronary syndrome.
Similar content being viewed by others
Abbreviations
- CAD:
-
coronary artery disease
- MI:
-
myocardial infarction
- UA:
-
unstable angina
- ACS:
-
acute coronary syndrome
- CVDs:
-
cardiovascular diseases
- IL6 :
-
the gene coding for interleukin-6
- IL10 :
-
the gene coding for interleukin-10
- LDL:
-
low density lipoproteins
- IS:
-
ischemic stroke
- AH:
-
arterial hypertension
References
Nazarenko G.I., Kleimenova E.B., Gushchina N.N. 2009. Studies on genetic markers and traditional risk factors of ischemic heart disease. Ross. Med. Vesti. 14, 47–54.
Oganov R.G. Pogosova G.V., Koltunov I.E., Belova Yu.S., Vygodin V.A. 2008. RELIF—REgulyarnoe Lechenie I proFilaktika (regular treatment and prophylaxis)—a key to improving the situation with cardiovascular diseases in Russia: Results of a Russian muilticenter study, part 3. Kardiologiya. 48, 46–53.
Agapkina Y.V., Nikitin A.G., Brovkin A.N., et al. 2010. Polymorphic markers G(−455)A of gene FGB and C(−654)T of gene PROC and genetic predisposition to unfavorable outcomes in patients undergoing acute coronary syndrome. Mol. Biol. 44 (in press).
Paoletti R., Gotto A.M., Hajjar D. P. 2004. Inflammation in atherosclerosis and implications for therapy. Circulation. 109, III-20–III-26.
Titov V.N. 1999. Association of atherosclerosis and ion-flammation: Specificity of atherosclerosis as an inflammatory process. Ross. Kardiol. Zh. 5, 24–29.
Berliner J.A., Navab M., Fogelman A.M., et al. 1995. Atherosclerosis: Basic mechanisms: Oxidation, inflammation, and genetics. Circulation. 91, 2488–2496.
Kavsak P.A., Newman A.M., Ko D.T., MacRae A.R., Jaffe A.S. 2010. The use of a cytokine panel to define the long-term risk stratification of heart failure/death in patients presenting with chest pain to the emergency department. Clin. Biochem. 43, 505–507.
Shavrin A., Khovaeva Ya., Chereshnev V., Golovskoy B. 2009. Inflammation markers in the course of atherosclerosis development. Kardiovask. Terap. Profilakt. 8, 13–15.
Zakirova N.E., Khafizov N.Kh., Karamova I.M., Zakirova A.N., Oganov R.G. 2007. Illunoinflammatory reactions in ischemic heart disease. Ratsion. Farmakoterap. Kardiol. 3, 16–19.
Oshchepkova E.V., Dmitriev V.A., Titov V.N., Rogoza A.N., Masenko V.P. 2007. Indices of unspecific inflammation in patients with hypertension disease. Terapevt. Arkhiv. 79, 18–25.
Vostrikova N., Fedorov D., Mamaev A., et al. 2009. Markers of inflammation markers (C-reactive protein and interleukin 6) in arterial hypertension. Sib. Med. Zh. 24, 33–34.
Papanicolaou D.A., Wilder R.L., Manolagas S.C., Chrousos G.P. 1998. The pathophysiologic roles of interleukin-6 in human disease. Ann. Intern. Med. 128(2), 127–137.
Aker S., Bantis C., Reis P., et al. 2009. Influence of interleukin-6 G-174C gene polymorphism on coronary artery disease, cardiovascular complications and mortality in dialysis patients. Nephrol. Dial. Transplant. 24, 2847–2851.
Sie M.P.S., Mattace-Raso F.U.S., Uitterlinden A.G., et al. 2008. The interleukin-6-174 G/C promoter polymorphism and arterial stiffness: The Rotterdam Study. Vasc. Health. Risk. Manag. 4, 863–869.
Manginas A., Tsiavou A., Chaidaroglou A., et al. 2008. Inflammatory cytokine gene variants in coronary artery disease patients in Greece. Coronary Artery Dis. 19, 575–582.
Shevchenko A., Golovanova O., Konenkov V., et al. 2009. Analysis of relationship between IL6 (−174 G/C) gene polymorphism and classic risk factors in patients with a history of acute myocardial infarction. Med. Immunol. 11, 557–566.
Li J., Guo Y., Yang Y. 2005. Enhancing anti-inflammatory cytokine IL-10 may be beneficial for acute coronary syndrome. Med. Hypoth. 65, 103–106.
Tedgui A., Mallat Z. 2001. Anti-inflammatory mechanisms in the vascular wall. Circ. Res. 88, 877–887.
Mallat Z., Besnard S., Duriez M., et al. 1999. Protective role of interleukin-10 in atherosclerosis. Circ. Res. 85, e17–e24.
Smith D.A., Irving S.D., Sheldon J., Cole D., Kaski J.C. 2001. Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation. 104, 746–749.
Reuss E., Fimmers R., Kruger A., et al. 2002. Differential regulation of interleukin-10 production by genetic and environmental factors: A twin study. Genes Immunol. 3, 407–413.
Suárez A., Castro P., Alonso R., Mozo L., Gutiérrez C. 2003. Interindividual variations in constitutive interleukin-10 messenger RNA and protein levels and their association with genetic polymorphisms. Transplantation. 75, 711–717.
Turner D.M., Williams D.M., Sankaran D., et al. 1997. An investigation of polymorphism in the interleukin-10 gene promoter. Eur. J. Immunogenet. 24, 1–8.
Schippers E.F., van’t Veer C., van Voorden S., et al. 2005. IL-10 and toll-like receptor-4 polymorphisms and the in vivo and ex vivo response to endotoxin. Cytokine. 29, 215–228.
Heiskanen M., Kähönen M., Hurme M., et al. 2010. Polymorphism in the IL10 promoter region and early markers of atherosclerosis: The cardiovascular risk in young Finns study. Atherosclerosis. 208, 190–196
Johns M.B., Paulus-Thomas J.E. 1989. Purification of human genomic DNA from whole blood using sodium perchlorate in place of phenol. Anal. Biochem. 180, 276–278.
Wang P., Wu P., Siegel M.I., Egan R.W., Billah M.M. 1995. Interleukin (IL)-10 inhibits nuclear factor B (NFB) activation in human monocytes. J. Biol. Chem. 270, 9558–9563.
Pinderski Oslund L.J., Hedrick C.C., Olvera T., et al. 1999. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 19, 2847–2853.
Von Der Thüsen J.H., Kuiper J., Fekkes M.L., et al. 2001. Attenuation of atherogenesis by systemic and local adenovirus-mediated gene transfer of interleukin-10 in LDLr−/− mice. FASEB J. 15, 2730–2732.
Pinderski L.J., Fischbein M.P., Subbanagounder G., et al. 2002. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient mice by altering lymphocyte and macrophage phenotypes. Circ. Res. 90, 1064–1071.
Malarstig A., Eriksson P., Hamsten A., et al. 2008. Raised interleukin-10 is an indicator of poor outcome and enhanced systemic inflammation in patients with acute coronary syndrome. Heart. 94, 724–729.
Mys-liwska J., Wieckiewicz J., Hak L., et al. 2006. Interleukin 6 polymorphism corresponds to the number of severely stenosed coronary arteries. Eur. Cytokine Netw. 17, 181–188.
Fishman D., Faulds G., Jeffery R., et al. 1998. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J. Clin. Invest. 102, 1369–1376.
Rivera-Chavez F.A., Peters-Hybki D.L., Barber R.C., O’Keefe G.E. 2003. Interleukin-6 promoter haplotypes and interleukin-6 cytokine responses. Shock. 20, 218–223.
Terry C.F., Loukaci V., Green F.R. 2000. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J. Biolog. Chem. 275, 18138–18144.
Adams D.H., Shaw S. 1994. Leucocyte-endothelial interactions and regulation of leucocyte migration. Lancet. 343, 831–836.
Zhou X., Stemme S., Hansson G.K. 1996. Evidence for a local immune response in atherosclerosis. CD4+ T cells infiltrate lesions of apolipoprotein-E-deficient mice. Am. J. Pathol. 149, 359–366.
Huber S.A., Sakkinen P., Conze D., Hardin N., Tracy R. 1999. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol. 19, 2364–2367.
Heinisch R.H., Zanetti C.R., Comin F., et al. 2005. Serial changes in plasma levels of cytokines in patients with coronary artery disease. Vasc. Health Risk Manag. 1, 245–250.
Pai J.K., Mukamal K.J., Rexrode K.M., Rimm E.B. 2008. C-reactive protein (CRP) gene polymorphisms, CRP levels, and risk of incident coronary heart disease in two nested case-control studies. PLoS ONE. 3, e1395.
Basso F., Lowe G.D., Rumley A., McMahon A.D., Humphries S.E. 2002. Interleukin-6-174G>C polymorphism and risk of coronary heart disease in West of Scotland coronary prevention study (WOSCOPS). Arterioscler. Thromb. Vasc. Biol. 22, 599–604.
Antonicelli R., Olivieri F., Bonafè M., et al. 2005. The interleukin-6-174 G>C promoter polymorphism is associated with a higher risk of death after an acute coronary syndrome in male elderly patients. Int. J. Cardiol. 103, 266–271.
Author information
Authors and Affiliations
Corresponding author
Additional information
Original Russian Text © K.A. Blagodatskikh, M.A. Evdokimova, Yu.V. Agapkina, A.G. Nikitin, A.N. Brovkin, A.A. Pushkov, E.G. Blagodatskikh, O.Yu. Kudryashova, V.S. Osmolovskaya, L.O. Minushkina, M.S. Kochkina, N.D. Selezneva, E.N. Dankovtseva, O.S. Chumakova, T.N. Baklanova, P.A. Talyzin, N.E. Reznichenko, O.P. Donetskaya, S.N. Tereshchenko, E.S. Krasil’nikova, N.A. Dzhaiani, E.V. Akatova, M.G. Glezer, A.S. Galyavich, V.B. Zakirova, N.A. Koziolova, I.V. Timofeeva, A.V. Yagoda, O.I. Boeva, L.I. Katel’nitskaya, E.V. Khorolets, S.V. Shlyk, E.G. Volkova, M.P. Margaryan, I.O. Guz’, V.O. Konstantinov, N.V. Timofeeva, B.A. Sidorenko, D.A. Zateishchikov, V.V. Nosikov, 2010, published in Molekulyarnaya Biologiya, 2010, Vol. 44, No. 5, pp. 839–846.
Rights and permissions
About this article
Cite this article
Blagodatskikh, K.A., Evdokimova, M.A., Agapkina, Y.V. et al. The polymorphisms G(−174)C in IL6 gene and G(−1082)A in IL10 gene are associated with poor outcomes in patients with acute coronary syndrome. Mol Biol 44, 741–747 (2010). https://doi.org/10.1134/S0026893310050092
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S0026893310050092